Dopamine sudden depletion as a model for mixed depression

Medical Hypotheses

Volumn 78, Issue 1, 2012, Pages 107-112

  Strejilevich, S A ^a   Teitelbaum, J ^a   Martino, D J ^a   Quiroz, D ^b   Kapczinski, F ^c  

^a FAVALORO UNIVERSITY   (Argentina)

^b Centro de Enfermedades del ánimo EFESO   (Chile)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT;

ARTICLE; BEHAVIOR DISORDER; BIPOLAR DISORDER; DEPRESSION; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; DYSPHORIA; MIXED DEPRESSION; NEUROCHEMISTRY; NEUROLEPTIC INDUCED DYSPHORIA; NEUROPATHOLOGY;

BIPOLAR DISORDER; DOPAMINE; DOWN-REGULATION; HUMANS; MODELS, BIOLOGICAL;

EID: 83155180321     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.10.004     Document Type: Article

References (68)

1. Weygandt W. über die Mischzustände des manisch-depressiven Irreseins 1899, Lehmann, Munich.
2. Kraëpelin E. Psychiatrie: Ein Lehrbuch fur Studirende und Aerzte. Sechste, vollstandig umgearbeitete Auflage 1899, Verlag von Johann Ambrosius Barth, Leipzig.
3. Kraëpelin E. Manic-depressive Insanity and Paranoia. 1921.
4. Salvatore P., Baldessarini R.J., Centorrino F., et al. Weygandt's on the mixed states of manic- depressive insanity: a translation and commentary on its significance in the evolution of the concept of bipolar disorder. Harv Rev Psychiatry 2002 Sep-Oct, 10(5):255-275.
5. Benazzi F. Challenging the unipolar-bipolar division: does mixed depression bridge the gap? Prog Neuropsychopharmacol Biol Psychiatry 2007 Jan 30, 31(1):97-103.
6. Dilsaver S.C., Chen Y.R., Shoaib A.M., Swann A.C. Phenomenology of mania: evidence for distinct depressed, dysphoric, and euphoric presentations. Am J Psychiatry 1999, 156(3):426-430.
7. Sato T., Bottlender R., Schröter A., Möller H.J. Frequency of manic symptoms during a depressive episode and unipolar 'depressive mixed state' as bipolar spectrum. Acta Psychiatr Scand 2003 Apr, 107(4):268-274.
8. Ghaemi S.N. All mixed up: on the absence of diagnostic guidelines for mixed states in the ISBD Diagnostic Guidelines Task Force Report. Bipolar Disord 2008, 10:129-130.
9. Tohen M., Frank E., Bowden C.L., et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009 Aug, 11(5):453-473.
10. Benazzi F. Defining mixed depression. Prog Neuropsychopharmacol Biol Psychiatry 2008 May 15, 32(4):932-939.
11. Yatham L.N., Kennedy S.H., Schaffer A., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009 May, 11(3):225-255.
12. Cousins D.A., Butts K., Young A.H. The role of dopamine in bipolar disorder. Bipolar Disord 2009 Dec, 11(8):787-806.
13. Drevets W.C., Price J.L., Simpson J.R.J., et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997, 386:824-827.
14. Dodd M.L., Klos K.J., Bower J.H., Geda Y.E., Josephs K.A., Ahlskog J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005 Sep, 62(9):1377-1381.
15. Jacobs D., Silverstone T. Dextroamphetamine-induced arousal in human-subjects as a model for mania. Psychol Med 1986, 16:323-329.
16. Gerner R.H., Post R.M., Bunney W.E. Dopaminergic-mechanism in mania. Am J Psychiatry 1976, 133:1177-1180.
17. Singh A., Althoff R., Martineau R.J., Jacobson J. Pramipexole, ropinirole, and mania in Parkinson's disease. Am J Psychiatry 2005 Apr, 162(4):814-815.
18. Bunney W.E., Brodie H.K.H., Murphy D.L., Goodwin F.K. Studies of alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania. Am J Psychiatry 1971, 127:872-881.
19. Kukopulos A., Reginaldi D., Laddomada P., Floris G., Serra G., Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol 1980 Jul, 13(4):156-167.
20. Verbeek D.E., van Riezen J., de Boer R.A., van Melle J.P., de Jonge P. A review on the putative association between beta-blockers and depression. Heart Fail Clin 2011 Jan, 7(1):89-99.
21. Lieberman A. Depression in Parkinson's disease - a review. Acta Neurol Scand 2006, 113:1-8.
22. Aiken C.B. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 2007, 68(8):1230-1236.
23. Gao K., Kemp D.E., Ganocy S.J., Gajwani P., Xia G., Calabrese J.R. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008 Apr, 28(2):203-209.
24. Mitchell P.B., Wilhelm K., Parker G., Austin M.P., Rutgers P., Malhi G.S. The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J Clin Psychiatry 2001 Mar, 62(3):212-216. quiz 217.
25. van Rossum I., Tenback D., van Os J. Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting. BMC Psychiatry 2009 Apr, 28:9-16.
26. Goswami U., Sharma A., Khastigir U., et al. Neuropsychological dysfunction, soft neurological signs and social disability in euthymic patients with bipolar disorder. Br J Psychiatry 2006, 188:366-373.
27. Goswami U., Gulrajani C., Varma A., et al. Soft neurological signs do not increase with age in euthymic bipolar subjects. J Affect Disord 2007, 103(1-3):99-103.
28. Martino D.J., Igoa A., Marengo E., Scápola M., Ais E.D., Strejilevich S.A. Cognitive and motor features in elderly people with bipolar disorder. J Affect Disord 2008 Jan, 105(1-3):291-295.
29. Berk M., Dodd S., Kauer-Sant'anna M., et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand 2007, (Suppl. 434):41-49.
30. Benazzi F. Which could be a clinically useful definition of depressive mixed state? Prog Neuropsychopharmacol Biol Psychiatry 2002 Oct, 26(6):1105-1111.
31. Benazzi F., Koukopoulos A., Akiskal H.S. Toward a validation of a new definition of agitated depression as a bipolar mixed state (mixed depression). Eur Psychiatry 2004, 19(2):85-90.
32. Benazzi F. The continuum/spectrum concept of mood disorders: is mixed depression the basic link? Eur Arch Psychiatry Clin Neurosci 2006 Dec, 256(8):512-515.
33. Koukopoulos A., Sani G., Koukopoulos A.E., Manfredi G., Pacchiarotti I., Girardi P. Melancholia agitata and mixed depression. Acta Psychiatr Scand 2007, (Suppl. 433):50-57.
34. Goodwin F.K., Jamison K.R. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression 2007, Oxford University Press, USA, 2nd ed.
35. Hollister L.E., Eikenberry D.T., Raffel S. Chlorpromazine in nonpsychotic patients with pulmonary tuberculosis. Am Rev Respir Dis 1960 Apr, 81:562-566.
36. Emerich D.F., Sanberg P.R. Neuroleptic dysphoria. Biol Psychiatry 1991 Feb, 29(3):201-203.
37. Hollister L.E. Neuroleptic dysphoria: so what's new? Biol Psychiatry 1992 Mar 1, 31(5):531-532.
38. Awad A.G., Voruganti L.N. Neuroleptic dysphoria: revisiting the concept 50 years later. Acta Psychiatr Scand 2005, (Suppl. 427):6-13.
39. Van Putten T., May P.R., Marder S.R., Wittmann L.A. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981 Feb, 38(2):187-190.
40. Halstead S.M., Barnes T.R., Speller J.C. Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br J Psychiatry 1994, 164:177-183.
41. Caine E.D., Polinsky R.J. Haloperidol-induced dysphoria in patients with Tourette's syndrome. Am J Psychiatry 1979 Sep, 136(9):1216-1217.
42. Belmaker R.H., Wald D. Haloperidol in normals. Br J Psychiatry 1977 Aug, 131:222-223.
43. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974, 31:67-72.
44. Van Putten T., May P.R. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry 1978, 35(4):477-480.
45. Van Putten T. The many faces of akathisia. Compr Psychiatry 1975, 16(1):43-47.
46. de Haan L., Booij J., Lavalye J., van Amelsvoort T., Linszen D. Subjective experiences during dopamine depletion. Am J Psychiatry 2005 Sep, 162(9):1755.
47. Voruganti L.N., Awad A.G. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia - findings from an in vivo SPECT study. Schizophr Res 2006 Dec, 88(1-3):179-186.
48. Rabinak C.A., Nirenberg M.J. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010 Jan, 67(1):58-63.
49. Morgan P.T., Pace-Schott E., Pittman B., Stickgold R., Malison R.T. Normalizing effects of modafinil on sleep in chronic cocaine users. Am J Psychiatry 2010 Mar, 167(3):331-340.
50. Harvey A.G. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry 2008 Jul, 165(7):820-829.
51. Volkow N.D., Fowler J.S., Logan J., et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009 Mar 18, 301(11):1148-1154.
52. Maricle R.A., Nutt J.G., Valentine R.J., Carter J.H. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double blind, placebo-controlled study. Neurology 1995 Sep, 45(9):1757-1760.
53. de Haan L., van Bruggen M., Lavalaye J., Booij J., Dingemans P.M., Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003, 160(2):303-309.
54. Van Putten T., May P.R., Jenden D.J., Cho A.K., Yale C. Plasma and saliva levels of chlorpromazine and subjective response. Am J Psychiatry 1980 Oct, 137(10):1241-1242.
55. Van Putten T. Vulnerability to extrapyramidal side effects. Clin Neuropharmacol 1983, 6(Suppl. 1):S27-S34.
56. Voruganti L., Slomka P., Zabel P., et al. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D2 binding ratios on SPECT imaging. Neuropsychopharmacology 2001, 25(5):642-650.
57. Lafuente A., Bernardo M., Mas S., et al. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Res 2008 Nov 30, 161(2):131-141.
58. Hegerl U., Sander C., Olbrich S., Schoenknecht P. Are psychostimulants a treatment option in mania? Pharmacopsychiatry 2009, 42(5):169-174.
59. Hegerl U., Himmerich H., Engmann B., Hensch T. Mania and attention-deficit/hyperactivity disorder: common symptomatology, common pathophysiology and common treatment? Curr Opin Psychiatry 2010, 23(1):1-7.
60. Goldberg J., Perlis R., Ghaemi S., et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry 2007, 164:1348-1355.
61. Tohen M., Sutton V., Calabrese J., Sachs G., Bowden C. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar I disorder. J Affect Disord 2009, 116:43-50.
62. Swann A., Bowden C., Calabrese J., Dilsaver S., Morris D. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002, 26:530-536.
63. Houston J., Tohen M., Degenhardt E., Jamal H., Liu L., Ketter T. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry 2009, 70:1540-1547.
64. Valentí M., Benabarre A., García-Amador M., Molina O., Bernardo M., Vieta E. Electroconvulsive therapy in the treatment of mixed states in bipolar disorder. Eur Psychiatry 2008 Jan, 23(1):53-56.
65. Costain D.W., Gelder M.G., Cowen P.J., Grahame-Smith D.G. Electroconvulsive therapy and the brain: evidence for increased dopamine mediated responses. The Lancet 1982, 2(8295):400-421.
66. Mann J.J., Kapur S. Elucidation of biochemical basis of the antidepressant action of electroconvulsive therapy by human studies. Psychopharmacol Bull 1994, 30(3):445-453.
67. Landau AM, Chakravarty MM, Clark CM, Zis AP, Doudet DJ. Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates. Neuropsychopharmacology 2011 Jan;36(2):511-8. Epub 2010 Oct 13.
68. Kumatoshi I., Masashi S. Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn J Pharmacol 1999, 80(3):185-189.